BioCeuticals UltraBiotic BS (30 capsules)
BioCeuticals UltraBiotic BS (30 capsules)
UltraBiotic BS contains an evidence-based, dairy-free blend of four probiotic strains known as LAB4 to support the health of the digestive system. It is shelf-stable, providing 25 billion CFU at room temperature and 45 billion CFU when refrigerated.
Dairy free and vegetarian friendly.
LAB4 probiotic blend
Each probiotic strain in UltraBiotic IBS has been selected for their natural gastric resistance, bile tolerance, enzymatic activity and scientific research for benefits in digestive health and function, immune health and function, and collectively have been demonstrated to provide symptomatic relief of medically diagnosed IBS, particularly a reduction in the number of days experiencing abdominal pain.
The LAB4 multistrain probiotic blend is clinically trialled in medically diagnosed IBS to:
- enhance quality of life
- provide satisfaction with bowel habits
- reduce number of days with abdominal pain.
IBS is a common digestion complaint affecting one in five Australians. Symptoms include:
- abdominal pain or cramping that is often relieved by passing wind or faeces
- abdominal bloating
- mucus present in the stools
- alternating constipation and diarrhoea.
People with IBS may have altered intestinal flora. Supplementing with L. acidophilus, B. animalis ssp. lactis and B. bifidum may promote a healthy intestinal ecosystem of bacterial flora.
A trial of 52 participants with IBS, as defined by the Rome II criteria, given 25 billion CFUs of the LAB4 or placebo for eight weeks showed a significantly greater improvement in the Symptom Severity Score of IBS and in scores for Quality of Life, Days with Pain, and Satisfaction with Bowel Habit than the placebo group.
When taken daily LAB4 was identified to provide temporary relief of the symptoms associated with IBS within 2-6 weeks of starting supplementation.
Effect of LAB4 vs control on IBS symptom severity
When to take probiotics
Probiotics should be taken with food. This is because the pH of an empty stomach is somewhere between 1.8 and 2.6; when you eat, the presence of food has a neutralising effect, increasing the pH to between 3.5 and 4.2, meaning it is nearly 100 times less acidic. Probiotic bacteria are much more likely to survive in this less acidic environment where it remains for approximately two hours awaiting movement into the small intestine.
The probiotic strains in UltraBiotic IBS are tested to ensure they can withstand the pH of the stomach when food is present. Most living organisms cannot survive a pH as low as 1.8; this is why there is very minimal colonisation within the stomach. Only extremely robust strains such as Helicobacter pylori will survive such acidic environments.
LAB4 probiotic blend in IBS
Background: The efficacy of probiotics in alleviating the symptoms of IBS appears to be both strain- and dose-related.
Subjects/Method: 52 participants with IBS, as defined by the Rome II criteria, given 25 billion CFUs of the LAB4 or placebo for 8 weeks.
Results: A significantly greater improvement in the Symptom Severity Score of IBS and in scores for Quality of Life, Days with Pain, and Satisfaction with Bowel Habit was observed in the volunteers receiving the probiotic preparation compared with the placebo group. LAB4 multistrain probiotic supplement at a daily dosage of 25 billion CFU may be beneficial for temporary symptom relief of IBS.
Williams E, Stimpson J, Wang D, et al. Clinical trial: a multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study. Aliment Pharmacol Ther 2008;29:97-103.
Probiotics during and after antibiotic therapy
Background: Disturbance of the microbiota is frequently associated with diarrhoea, gastritis, glossitis and pruritus as well as fungal infections.
Subjects/Method: 155 patients infected with Helicobacter pylori in this double-blind, placebo-controlled trial received antibiotics (standard eradication therapy: amoxicillin 1g, clarithromycin 500mg and lansoprazole 30mg, twice daily) from days 1-7. The active group (n=76) received probiotics (Lactobacillus acidophilus CUL 60 + CUL 21 and two strains of Bifidobacterium spp.) from days 1-21, while the control group (n=79) received placebo.
Results: Despite the probiotic supplement, the microbiota of both the control and active groups were susceptible to the effects of the administered antibiotics. However, supplementation with probiotics resulted in less disruption of the compositional balance in the active group compared with the control group. Daily supplementation with viable probiotic bacteria during and after antibiotic therapy reduces the extent of disruption to the intestinal microbiota as well as the incidence and total numbers of antibiotic-resistant strains in the regrowth population.
Plummer SF, Garaiova I, Sarvotham T, et al. Effects of probiotics on the composition of the intestinal microbiota following antibiotic therapy. Int J Antimicrob Agents 2005;26(1):69-74.
- If diarrhoea persists for more than 6 hours in infants under 6 months, 12 hours in children under 3 years, 24 hours in children aged 3-6 years or 48 hours in adults and children over 6 years, seek medical advice.
- Mild, temporary gastrointestinal disturbances, such as increased flatulence, may occur with amounts exceeding one billion live organisms. If this occurs reduce the dose, then gradually increase it over time.
- It is recommended to take probiotics at least four hours away from antibiotics to limit a potential reduction in probiotic effectiveness.
 Hawrelak JA. Probiotics. In: Pizzorno JE, Murray MT (Eds), Textbook of natural medicine, 3rd ed (pp.1195-1215). St Louis: Churchill Livingstone Elsevier, 2006.
 Williams EA, Stimpson J, Wang D, et al. Clinical trial: a multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo- controlled study. Aliment Pharmacol Ther 2009;29(1):97-103.
 Irritable bowel syndrome. Better Health Channel 2012. Viewed 10 Feb 2014, http://www.betterhealth.vic.gov.au/bhcv2/bhcarticles.nsf/pages/Irritable_bowel_syndrome